Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/14/2010WO2010052475A1 Process for resolving zopiclone
05/14/2010WO2010052466A2 Pharmaceutical aerosol composition
05/14/2010WO2010052450A1 Tiotropium bromide having a low degree of crystallinity
05/14/2010WO2010052448A2 Fused pyrazine derivatives as kinase inhibitors
05/14/2010WO2010052445A1 Medicament and method of diagnosis
05/14/2010WO2010052430A2 Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
05/14/2010WO2010052394A1 Ivabradine used as a diagnosis agent in a method for coronary angiography using multiple-cut tomodensitometry
05/14/2010WO2010052329A1 The use of compounds to inhibit 5a-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing them
05/14/2010WO2010052328A1 Diene compounds for use in human epidermal cell repair, and pharmaceutical and cosmetic compositions containing them
05/14/2010WO2010052327A1 Novel anti-stretch mark active agent, and compositions containing same
05/14/2010WO2010052310A1 Alpha-lipoic acid derivatives and their use in drug preparation
05/14/2010WO2010052256A1 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
05/14/2010WO2010052253A1 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
05/14/2010WO2010052222A1 (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
05/14/2010WO2010052199A1 Heterocyclic gamma secretase modulators
05/14/2010WO2010052198A1 ( pyrrolidin-2 -yl) phenyl derivatives for use in the treatment of pain
05/14/2010WO2010052027A1 Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
05/14/2010WO2010051996A1 Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
05/14/2010WO2010051977A1 Substituted disulfonamides as bri-modulators
05/14/2010WO2010051961A1 Chemical synthesis of phosphatidylinositol mannoside glycans from mycobacterium tuberculosis
05/14/2010WO2010051935A2 Substituted amido phenoxybenzamides
05/14/2010WO2010051933A2 Substituted sulphonamido phenoxybenzamides
05/14/2010WO2010051926A2 New halogen-substituted bonds
05/14/2010WO2010051819A1 Novel 2,3-diamino-quinazolinone derivatives and their medical use
05/14/2010WO2010051781A1 Kinase inhibitors and their use as pharmaceutical agents
05/14/2010WO2010051683A1 A composition useful for treating acute enteritis and diarrhea
05/14/2010WO2010051664A1 7h-imidazo[1,20-a]pyrano[2,3-c]pyridine derivations and the use thereof
05/14/2010WO2010051639A1 Use of mir-126 for enhancing hematopoietic stem cell engraftment, for isolating hematopoietic stem cells, and for treating and monitoring the treatment of acute myeloid leukemia
05/14/2010WO2010051636A1 Combination of an oxidant and a photoactivator for the healing of wounds
05/14/2010WO2010051631A1 Method and composition for enhancement of male erectile function
05/14/2010WO2010037066A3 Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
05/14/2010WO2010033643A3 Small molecule compounds for stem cell differentiation
05/14/2010WO2010033043A8 Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
05/14/2010WO2010030995A3 Local delivery of water-soluble or water-insoluble therapeutic agents to the surface body lumens
05/14/2010WO2010027189A9 A new use for homoisoflavanone or a salt thereof
05/14/2010WO2010023473A3 Crystalline form of sunitinib and processes for its preparation
05/14/2010WO2010021882A3 Cold menthol receptor antagonists
05/14/2010WO2010019847A3 Aptamer inhibition of thrombus formation
05/14/2010WO2010019210A3 Halofuginone analogs for inhibition of trna synthetases and uses thereof
05/14/2010WO2010017918A3 Amorphous ambrisentan
05/14/2010WO2010017443A3 Anti-beta-2-microglobulin agents and the use thereof
05/14/2010WO2010017343A3 Flupirtine hydrochloride maleic acid cocrystal
05/14/2010WO2010017264A3 Photo-crosslinked nucleic acid hydrogels
05/14/2010WO2010017135A3 Novel forms of eperisone
05/14/2010WO2010017093A3 Dopamine receptor ligands with enhanced duration of action
05/14/2010WO2010015652A3 Thiazole compounds as medicaments for the treatment of (inter alia) cardiovascular diseases
05/14/2010WO2010014883A3 Azacitidine process and polymorphs
05/14/2010WO2010014798A3 Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
05/14/2010WO2010014739A3 Heterocyclic modulators of tgr5
05/14/2010WO2010014240A3 Novel bioactive small molecules derived from sea sponges
05/14/2010WO2010014199A3 Uses of morelloflavone
05/14/2010WO2010013224A4 Curcumin nanoparticles and methods of producing the same
05/14/2010WO2010011868A3 Pyridine sulfonamide modulators of endothelin-a-receptor
05/14/2010WO2010011700A3 Treatment of cancers characterized by chromosomal rearrangement of the nut gene
05/14/2010WO2010011605A3 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
05/14/2010WO2010011599A3 Pimethixene derivatives for promoting bone growth
05/14/2010WO2010011111A4 Composition for control of aging and / or extension of life, containing dapsone as active ingredient
05/14/2010WO2010010531A3 Composition for controlling increase in blood glucose
05/14/2010WO2010009405A3 Targeted nitroxide agents
05/14/2010WO2010009342A3 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
05/14/2010WO2010008244A3 Pharmaceutical preparation
05/14/2010WO2010006184A3 Small-molecule inhibitors of hif and angiogenesis
05/14/2010WO2010005980A8 Tacrolimus for improved treatment of transplant patients
05/14/2010WO2010005572A3 Alpha-keto heterocycles as faah inhibitors
05/14/2010WO2010002429A9 Synergistic antimicrobial mixtures
05/14/2010WO2009158526A3 Methods of reducing cellular proliferation by inhibiting acsvl3
05/14/2010WO2009156678A3 Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
05/14/2010WO2009156484A3 Organic compounds
05/14/2010WO2009153434A3 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity on the inflammatory response
05/14/2010WO2009152167A3 Delivery of therapeutics
05/14/2010WO2009151496A4 Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
05/14/2010WO2009149053A3 Naproxcinod process and solid dispersion
05/14/2010WO2009145814A9 Pyrimidines and pyridines useful as inhibitors of protein kinases
05/14/2010WO2009134616A8 Novel inhibitors of hepatitis c virus replication
05/14/2010WO2009120389A8 Oral and injectable formulations of tetracycline compounds
05/14/2010WO2009106824A3 Pharmaceutical formulations with a taste masking coating
05/14/2010WO2009104054A8 Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
05/14/2010WO2009097515A3 [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
05/14/2010WO2009066309A9 Process for preparation of omeprazole
05/14/2010WO2009057795A8 Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
05/14/2010WO2009050580A8 Composition for regulating lipid metabolism
05/14/2010WO2009041799A8 Pharmaceutical composition combining diacerein and chondroitin sulphate and use thereof in the treatment of osteoarthritis and related diseases
05/14/2010WO2009041798A8 Pharmaceutical compositions combining a nonsteroidal anti-inflammatory agent and a xanthine oxidase inhibiting agent, which can be used to control and treat gout, gouty arthritis and related diseases
05/14/2010WO2009033140A9 Microrna signatures in human ovarian cancer
05/14/2010WO2007087129A8 Fluorinated arylamide derivatives
05/14/2010CA2779958A1 Role of soluble upar in the pathogenesis of proteinuric kidney disease
05/14/2010CA2778961A1 Compounds and methods for the treatment of inflammatory diseases of the cns
05/14/2010CA2778938A1 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
05/14/2010CA2765402A1 Pirfenidone treatment for patients with atypical liver function
05/14/2010CA2746054A1 Small molecule modulators of epigenetic regulation and their therapeutic applications
05/14/2010CA2744820A1 Process for obtaining a rosuvastatin calcium composition and obtained product
05/14/2010CA2743216A1 The use of compounds to inhibit 5a-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing them
05/14/2010CA2743212A1 Diene compounds for use in human epidermal cell repair, and pharmaceutical and cosmetic compositions containing them
05/14/2010CA2743196A1 Heterocyclic gamma secretase modulators
05/14/2010CA2743134A1 Compounds useful as inhibitors of atr kinase
05/14/2010CA2742991A1 Microrna-mediated regulation of ubc9 expression in cancer cells
05/14/2010CA2742986A1 Use of catecholic butane derivatives in cancer therapy
05/14/2010CA2742980A1 Modulators of atp-binding cassette transporters
05/14/2010CA2742973A1 Low dose lipoic acid pharmaceutical compositions and methods
05/14/2010CA2742964A1 Medicament and method of diagnosis
1 ... 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 ... 7860